Daiichi Sankyo Pharma Development

FDA Regulatory Profile

Daiichi Sankyo Pharma Development appears in FDA public data with 8 recalls, 0 510(k) clearances, 0 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-1508-2014, Class II) was initiated on July 12, 2014.

Summary

Total Recalls
8
510(k) Clearances
0
Inspections
0
Compliance Actions
0

Recent Recalls

NumberClassProductDate
D-1508-2014Class IIBenicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/25 mg, 30 and 90 count bottles,July 12, 2014
D-1506-2014Class IIBenicar Tablets (olmesartan medoxomil) 40 mg, 30 and 90 count, Rx Only Manufactured for: Daiichi SanJuly 12, 2014
D-1503-2014Class IIBenicar HCT Tablets (olmesartan medoxomil, hydrochlorothiazide) 20 mg/12.5 mg, 30 count bottles, Rx July 12, 2014
D-1501-2014Class IIAzor Tablets (amlodipine and olmesartan medoxomil) 10 mg*/40 mg, 30 count bottles, Rx Only, ManufactJuly 12, 2014
D-1504-2014Class IITribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count July 12, 2014
D-1505-2014Class IIWelchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi SankJuly 12, 2014
D-1507-2014Class IIBenicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx OJuly 12, 2014
D-1502-2014Class IIBenicar Tablets (olmesartan medoxomil) 20 mg, 30 and 90 count, Rx Only Manufactured for: Daiichi SanJuly 12, 2014